Probability 20.2% 27.3% HRc of disability (95% CI): progression 0.70 at Week (0.51, 108 0.97) 0.0279b MRI Endpoint Burden of disease 0.723 (7.59) 2.208 (7.00) (mL) Mean (SD) LSM change mean 0.045 (0.30) 0.111 (0.31) from difference [0.043 (0.02)] [0.132 (0.02)] baseline at (SE) from Week 108 placebo: -0.089 Mean (SD) (0.025) [LSM (SE)] 0.0003b change in absolute of cubic root transformed BOD from baseline at Week 108 Number of 0.261 1.331 RRa (95% CI): 0.196 T1 lesion (0.120, per MRI 0.321) scan at <0.0001b Week 108
Probability of disability progression at Week 108 20.2% 27.3% HRc (95% CI): 0.70 (0.51, 0.97) 0.0279b MRI Endpoint Burden of disease (mL) Mean (SD) change from baseline at Week 108 Mean (SD) [LSM (SE)] change in absolute of cubic root transformed BOD from baseline at Week 108 0.723 (7.59) 0.045 (0.30) [0.043 (0.02)] 2.208 (7.00) 0.111 (0.31) [0.132 (0.02)] LSM mean difference (SE) from placebo: -0.089 (0.025) 0.0003b Number of T1 lesion per MRI scan at Week 108 0.261 1.331 RRa (95% CI): 0.196 (0.120, 0.321) <0.0001b
auspar-teriflunomide-130521-pi.docx